dalteparin has been researched along with Carcinoma, Non-Small Cell Lung in 14 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor mutations, but patients tend to develop resistance after an average of 10 months." | 1.42 | Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation. ( Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L, 2015) |
| "Massive pulmonary embolisms were shown by means of the computerized tomography." | 1.37 | Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases. ( Antonelli, G; Colina, P; Ferraù, F; Giamo, V; Parisi, A; Rotondo, S; Sessa, E; Vitale, FV, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Wilts, IT | 1 |
| Hutten, BA | 1 |
| Meijers, JCM | 1 |
| Spek, CA | 1 |
| Büller, HR | 2 |
| Kamphuisen, PW | 1 |
| Groen, HJM | 1 |
| van der Heijden, EHFM | 1 |
| Klinkenberg, TJ | 1 |
| Biesma, B | 1 |
| Aerts, J | 1 |
| Verhagen, A | 1 |
| Kloosterziel, C | 1 |
| Pieterman, R | 1 |
| van den Borne, B | 1 |
| Smit, HJM | 1 |
| Hoekstra, O | 1 |
| Schramel, FMNH | 1 |
| van der Noort, V | 1 |
| van Tinteren, H | 1 |
| Smit, EF | 1 |
| Dingemans, AC | 1 |
| Vitale, FV | 1 |
| Rotondo, S | 1 |
| Sessa, E | 1 |
| Antonelli, G | 1 |
| Colina, P | 1 |
| Parisi, A | 1 |
| Giamo, V | 1 |
| Ferraù, F | 1 |
| van Doormaal, FF | 1 |
| Di Nisio, M | 1 |
| Otten, HM | 1 |
| Richel, DJ | 1 |
| Prins, M | 1 |
| Züger, M | 1 |
| Demarmels Biasiutti, F | 1 |
| Wuillemin, WA | 1 |
| Furlan, M | 1 |
| Lämmle, B | 1 |
| Alturkistani, A | 1 |
| Ghonem, N | 1 |
| Power-Charnitsky, VA | 1 |
| Pino-Figueroa, A | 1 |
| Migliore, MM | 1 |
| Esme, H | 1 |
| Can, A | 1 |
| Şehitogullari, A | 1 |
| Miller, RE | 1 |
| Jones, JC | 1 |
| Tometsko, M | 1 |
| Blake, ML | 1 |
| Dougall, WC | 1 |
| Pan, Y | 1 |
| Li, X | 2 |
| Duan, J | 1 |
| Yuan, L | 1 |
| Fan, S | 1 |
| Fan, J | 1 |
| Xiaokaiti, Y | 1 |
| Yang, H | 1 |
| Wang, Y | 1 |
| Abu Arab, W | 1 |
| Kotb, R | 1 |
| Sirois, M | 1 |
| Rousseau, E | 1 |
| Robert, F | 1 |
| Busby, E | 1 |
| Marques, MB | 1 |
| Reynolds, RE | 1 |
| Carey, DE | 1 |
| Meyer, G | 2 |
| Besse, B | 2 |
| Doubre, H | 1 |
| Charles-Nelson, A | 1 |
| Aquilanti, S | 1 |
| Izadifar, A | 1 |
| Azarian, R | 2 |
| Monnet, I | 2 |
| Lamour, C | 1 |
| Descourt, R | 2 |
| Oliviero, G | 1 |
| Taillade, L | 2 |
| Chouaid, C | 2 |
| Giraud, F | 2 |
| Falcoz, PE | 1 |
| Revel, MP | 1 |
| Westeel, V | 1 |
| Dixmier, A | 1 |
| Tredaniel, J | 1 |
| Dehette, S | 1 |
| Decroisette, C | 1 |
| Prevost, A | 1 |
| Pichon, E | 2 |
| Fabre, E | 1 |
| Soria, JC | 1 |
| Friard, S | 2 |
| Stern, JB | 1 |
| Jabot, L | 1 |
| Dennewald, G | 2 |
| Pavy, G | 1 |
| Petitpretz, P | 1 |
| Tourani, JM | 1 |
| Alifano, M | 2 |
| Chatellier, G | 2 |
| Girard, P | 2 |
| Matikas, A | 1 |
| Vardakis, N | 1 |
| Souglakos, J | 1 |
| Georgoulias, V | 1 |
| Corbi, P | 1 |
| De Luca, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial to Evaluate the Effects of Nadroparin on Survival and Disease Progression in Patients With Advanced Malignancies of the Lung, Pancreas, or Prostate[NCT00312013] | Phase 3 | 503 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Effect of Low Molecular Weight Heparin on Survival of Stage I,II or IIIA Non Small Cell Lung Cancer. A Multicenter, Open, Randomized Controlled Trial.[NCT00475098] | Phase 3 | 553 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for dalteparin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Association between protein C levels and mortality in patients with advanced prostate, lung and pancreatic cancer.
Topics: Aged; Anticoagulants; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female | 2017 |
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2019 |
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2011 |
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung | 2003 |
Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, | 2018 |
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Follow-Up Studies; He | 2011 |
8 other studies available for dalteparin and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases.
Topics: Anticoagulants; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cerebellar Neoplasms; Dyspnea; Fem | 2011 |
Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.
Topics: Aged; Anticoagulants; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Humans; Injections, S | 1997 |
Inhibition of PAR-1 Receptor Signaling by Enoxaparin Reduces Cell Proliferation and Migration in A549 Cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung | 2019 |
Does the use of postoperative low-molecular-weight heparin in patients with lung cancer increase tube drainage?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drainage; Enoxaparin; Female; Heparin, Low-Molecular-Weight; H | 2020 |
RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Topics: Animals; Anticoagulants; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Enoxaparin; Female; Humans; | 2014 |
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, | 2015 |
Concentration- and time-dependent effects of enoxaparin on human adenocarcinomic epithelial cell line A549 proliferation in vitro.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Prolif | 2011 |
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol | 2013 |